Why Clinical Trials Miss Recruitment Targets-and What Sponsors Can Do Earlier

Understanding why recruitment challenges often begin long before the first participant is screened.


  • Home
  • Blog
  • Why Clinical Trials Miss Recruitment Targets-and What Sponsors Can Do Earlier
Why Clinical Trials Miss Recruitment Targets-and What Sponsors Can Do Earlier
Nov 16, 2026

Patient recruitment remains one of the most persistent operational challenges in clinical research.

A protocol may be scientifically sound. Regulatory approvals may be obtained. Sites may be activated. Investigators may be enthusiastic.

Yet enrollment may still fall significantly below expectations.

The immediate response is often familiar:

Open more sites. Add more countries. Increase recruitment activities. Extend the timeline.

These measures can sometimes help.

But they do not necessarily address the underlying problem.

In many cases, recruitment difficulties are not created when enrollment begins. They originate during protocol development, feasibility assessment, site selection and study planning.

For sponsors, the most important question is therefore not simply:

How can we recruit more participants?

It is:

What could prevent the right participants from entering and remaining in this trial—and how early can we address those barriers?

1. Recruitment Failure Is a Scientific and Operational Problem

Recruitment difficulties have consequences beyond delayed milestones.

A retrospective analysis by Kasenda and colleagues examined 1,017 randomized clinical trials approved by research ethics committees in several countries. Approximately one-quarter were discontinued prematurely, with poor recruitment the most frequently reported reason for discontinuation [1].

When trials fail to recruit adequately, the consequences may include:

  • Insufficient statistical power
  • Delayed development timelines
  • Increased operational expenditure
  • Reduced precision of treatment-effect estimates
  • Inconclusive study results
  • Wasted investigator and participant contributions

Recruitment is therefore not simply a project-management metric.

It is connected to the scientific validity and ethical value of clinical research.

2. Disease Prevalence Does Not Equal Recruitable Population

A common feasibility mistake is assuming that the number of patients with a disease represents the number of participants available for a study.

Consider a hypothetical hospital managing 1,000 patients annually with a particular condition.

After applying the protocol:

  • 400 may have the required disease stage.
  • 200 may satisfy previous-treatment criteria.
  • 100 may meet laboratory requirements.
  • 60 may have no relevant exclusion criteria.
  • 35 may be available during the recruitment period.
  • 20 may agree to participate.
  • 15 may ultimately be enrolled.

These numbers are illustrative, but the principle is important.

Available patients ≠ eligible patients ≠ recruitable patients ≠ enrolled participants.

Sponsors need realistic patient funnels supported by clinical and site-level evidence.

3. Protocol Complexity Can Reduce Recruitment

Eligibility criteria are intended to protect participants and support interpretable results.

However, unnecessarily restrictive criteria may limit access without adding proportional scientific value.

Other design features can create additional barriers:

  • Frequent hospital visits
  • Extensive laboratory testing
  • Long assessment days
  • Complex treatment schedules
  • Prolonged follow-up
  • Restrictive concomitant medication requirements
  • Inconvenient assessment windows

ICH E8(R1) encourages sponsors to identify factors critical to quality during study design and consider the feasibility of trial procedures [2].

Recruitment feasibility should therefore be assessed before protocol finalization, not only after the protocol has been approved.

4. Investigator Estimates Need Validation

Investigators provide essential knowledge of their patient populations.

But estimated recruitment capacity should be evaluated systematically.

When an investigator predicts enrollment of five participants per month, sponsors should ask:

How many potentially eligible patients were seen historically?

How many satisfy the major eligibility criteria?

How many competing trials are recruiting?

How frequently are suitable patients referred?

What was the site's previous enrollment performance?

Does the site have sufficient research staff?

An optimistic estimate is not necessarily an inaccurate estimate.

However, it should be treated as an assumption requiring supporting evidence.

5. Competing Trials Can Change the Recruitment Landscape

A site may have substantial access to the target population but be involved in several competing studies.

These studies may offer:

  • Broader eligibility
  • Fewer procedures
  • Different investigational treatments
  • More convenient schedules
  • Alternative treatment options

Competition may also change after feasibility has been completed.

Sponsors should therefore reassess recruitment assumptions when new trials enter the same therapeutic area.

Feasibility is a continuing activity, not a single questionnaire completed during study start-up.

6. Site Resources Matter as Much as Patient Access

A principal investigator may have excellent clinical expertise and access to patients.

But recruitment depends on the wider site team.

Clinical Research Coordinators, research nurses, pharmacists, laboratory personnel and administrative teams contribute to screening, scheduling, consent coordination, treatment and follow-up.

A site with inadequate CRC capacity may struggle even when eligible patients are available.

Sponsors should assess:

  • Research staffing
  • Competing workload
  • Investigator availability
  • Screening procedures
  • Referral coordination
  • Data-entry capacity
  • Participant follow-up resources

The objective is to identify sites capable of converting realistic patient access into reliable trial participation.

7. Patient Burden Must Be Evaluated

Patients do not make participation decisions solely on scientific eligibility.

They may consider:

Travel distance

Time away from employment

Caregiving responsibilities

Visit duration

Additional procedures

Potential adverse effects

Financial implications

Uncertainty about treatment

Recruitment strategies should therefore include appropriate patient-facing communication and practical measures to reduce unnecessary burden.

Depending on the study and applicable requirements, these may include flexible scheduling, appropriate reimbursement, local assessments or decentralized trial elements.

Such measures must remain consistent with the protocol, ethical requirements and participant protection.

8. Retention Is Part of Recruitment Planning

Recruitment targets are meaningful only if the study can retain enough participants to generate interpretable evidence.

A trial may meet its enrollment target but still experience substantial missing outcome data because participants discontinue follow-up.

Sponsors should therefore distinguish between:

Enrollment

Treatment adherence

Treatment discontinuation

Study withdrawal

Loss to follow-up

These are not interchangeable outcomes.

A participant who stops investigational treatment may still be able to contribute valuable follow-up information, subject to consent and the protocol.

Retention planning should begin during study design.

9. Recruitment Forecasts Should Be Updated Using Actual Performance

Once recruitment begins, sponsors should compare assumptions with reality.

Useful indicators include:

  • Actual versus projected screening
  • Screen-failure rates
  • Enrollment per active site
  • Time from activation to first participant
  • Recruitment by country
  • Participant withdrawal
  • Referral conversion
  • Site staffing changes

However, metrics need interpretation.

A high screen-failure rate may indicate overly optimistic feasibility, a restrictive protocol or a deliberate screening strategy.

The cause determines the intervention.

10. Why Opening More Sites Is Not Always the Answer

Adding sites increases operational complexity and cost.

It may require additional:

  • Regulatory and ethics submissions
  • Contracting
  • Monitoring
  • Investigational product supply
  • Training
  • Vendor coordination
  • Quality oversight

If the underlying problem is an excessively restrictive protocol, opening more sites may simply reproduce the same problem across a larger network.

Sponsors should first identify whether the recruitment barrier is:

Protocol-related

Population-related

Site-related

Operational

Competitive

Participant-related

Only then should corrective action be selected.

11. A Practical Recruitment Risk Framework for Sponsors

Before activating sites, sponsors should evaluate five dimensions.

1. Population: Is the eligible population supported by evidence?

2. Access: Can the proposed sites realistically reach those patients?

3. Participation: Can patients reasonably undertake the study procedures?

4. Delivery: Do sites have the staff and infrastructure to recruit and retain participants?

5. Timeline: Will sites activate early enough to contribute meaningfully?

During the trial, these assumptions should be reviewed against observed performance.

This creates a continuous process:

Feasibility → Recruitment → Performance Review → Root Cause Assessment → Targeted Intervention

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we believe recruitment planning should begin before site activation and remain connected to clinical operations, feasibility, data management and study governance.

Effective recruitment strategies require:

  • Evidence-based feasibility
  • Realistic patient-population estimates
  • Appropriate site selection
  • Early identification of protocol barriers
  • Adequate CRC and investigator capacity
  • Participant-centered study execution
  • Continuous performance review

The objective is not simply to recruit faster.

It is to recruit appropriately, retain participants wherever possible and generate the evidence needed to answer the study's scientific question.

The best recruitment strategy is not the one that reacts fastest to delays. It is the one that identifies preventable barriers before they become delays.

References

  1. Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311(10):1045–1051. doi:10.1001/jama.2014.1361.
  2. International Council for Harmonisation. ICH E8(R1): General Considerations for Clinical Studies. 2021.
  3. International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice. 2025.
  4. Huang GD, Bull J, Johnston McKee K, et al. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials. 2018;66:74–79. doi:10.1016/j.cct.2018.01.003.
  5. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database of Systematic Reviews. 2018;(2). doi:10.1002/14651858.MR000013.pub6.